Omega-3 Fatty Acids: Systemic Physiology, Pediatric Requirements, Dietary Sources, and Evidence-Based Dosing

Molecular properties characterizing the primary omega-3 species:

• Alpha-Linolenic Acid (ALA, 18:3 n-3): Terrestrial plant-derived essential precursor fatty acid supplying metabolic energy and baseline elongation substrate.
• Eicosapentaenoic Acid (EPA, 20:5 n-3): Marine fatty acid with 5 double bonds; core enzymatic substrate driving synthesis of 3-series prostaglandins, 5-series leukotrienes, and E-series resolvins.
• Docosahexaenoic Acid (DHA, 22:6 n-3): Conformationally flexible 22-carbon lipid with 6 double bonds; primary structural constituent of grey matter neural synapses and retinal photoreceptors.

Multisystem clinical virtues confirmed across adult populations:

• Cardiovascular Risk Reduction: Stabilizes myocardial electrophysiology, reducing susceptibility to ventricular arrhythmias and sudden cardiac death.
• Triglyceride and Hemodynamic Control: Suppresses hepatic VLDL secretion to reduce triglycerides by up to 30% while enhancing endothelial nitric oxide vasodilation.
• Resolution Pharmacology: Competitively displaces pro-inflammatory arachidonic acid, yielding SPMs that actively resolve chronic vascular and tissue inflammation.

Crucial physiological mandates across pediatric growth:

• Synaptogenesis in the First 1,000 Days: DHA accretion dictates dendritic arborization, synaptic plasticity, and myelination speed in developing neural networks.
• Visual Acuity Maturation: Sustained infant DHA saturation correlates directly with advanced stereoscopic visual acuity and contrast sensitivity milestones.
• Cognitive Function and ADHD Modulation: Controlled clinical trials confirm that targeted omega-3 supplementation (EPA/DHA blends) enhances attention spans, reading comprehension, and impulse regulation in school-aged children.

Comparative analysis of food matrix bioavailability:

• Cold-Water Pelagic Fish: Atlantic mackerel (4500 mg/100 g), wild herring (2500 mg/100 g), salmon (2200 mg/100 g), and sardines (1500 mg/100 g) provide direct, highly bioavailable phospholipid- and triglyceride-bound EPA/DHA.
• Microalgae Oil (Schizochytrium): The primary ecological source for marine omega-3; delivers pure, sustainable vegan EPA/DHA free from mercury, microplastics, and PCBs.
• Terrestrial ALA Matrices: Cold-pressed flaxseed oil (>50% ALA), chia seeds, and walnuts provide plant ALA; physiological conversion rates into active EPA/DHA remain constrained below 5% and 1%, respectively.

Consensus intake guidelines issued by international health bodies:

• Infants (Weaning up to 2 Years): 100 mg daily of pure preformed DHA.
• Pediatric Populations (Ages 2 to 12): 250 mg combined EPA + DHA daily to optimize neurodevelopment and immune resilience.
• Adult General Population: 250 mg to 500 mg combined EPA/DHA daily for primary cardiovascular defense.
• Therapeutic Regimens: Hypertriglyceridemia, autoimmune joint inflammation, and affective disorders warrant 2000 mg to 4000 mg combined EPA/DHA daily under clinical guidance.
• EFSA Safety Margin: Supplemental intakes up to 5000 mg EPA/DHA daily are classified as thoroughly safe for the adult general public.